Why Investors Shouldn't Be Surprised By Austar Lifesciences Limited's (HKG:6118) Low P/S
Jan 08
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedJan 15, 2026
DataAggregated Company Financials
Companies11
- 7D11.4%
- 3M7.2%
- 1Y132.1%
- YTD23.5%
In the last week, the Life Sciences industry is up 16%, with WuXi Biologics (Cayman) up 11%. In the last 12 months, the industry was up 128%. As for the next few years, earnings are expected to grow by 34% per annum.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 15 Jan 2026 | HK$369.6b | HK$42.7b | HK$6.4b | 49.7x | 58.2x | 8.7x |
| Sat, 13 Dec 2025 | HK$308.9b | HK$42.2b | HK$6.3b | 44.9x | 49.3x | 7.3x |
| Mon, 10 Nov 2025 | HK$324.1b | HK$41.8b | HK$6.2b | 47.4x | 52.2x | 7.7x |
| Wed, 08 Oct 2025 | HK$396.2b | HK$41.9b | HK$6.2b | 52.9x | 63.8x | 9.5x |
| Fri, 05 Sep 2025 | HK$316.0b | HK$41.9b | HK$6.2b | 46.7x | 50.9x | 7.5x |
| Sun, 03 Aug 2025 | HK$272.4b | HK$37.1b | HK$2.7b | 57.3x | 100x | 7.3x |
| Tue, 01 Jul 2025 | HK$226.4b | HK$37.3b | HK$2.7b | 42.7x | 82.4x | 6.1x |
| Thu, 29 May 2025 | HK$193.5b | HK$36.1b | HK$2.6b | 26x | 74.4x | 5.4x |
| Sat, 26 Apr 2025 | HK$188.9b | HK$35.4b | HK$2.5b | 25.9x | 74.6x | 5.3x |
| Mon, 24 Mar 2025 | HK$217.0b | HK$32.6b | -HK$203,413,550.89 | 47.8x | -1066.9x | 6.6x |
| Wed, 19 Feb 2025 | HK$195.8b | HK$35.8b | -HK$1,058,538,751.45 | 61.4x | -184.9x | 5.5x |
| Fri, 17 Jan 2025 | HK$151.1b | HK$35.6b | -HK$1,062,252,938.54 | 56.1x | -142.3x | 4.2x |
| Sun, 15 Dec 2024 | HK$154.0b | HK$35.8b | -HK$1,058,466,824.67 | 58.8x | -145.5x | 4.3x |
| Tue, 12 Nov 2024 | HK$151.9b | HK$36.1b | -HK$1,055,366,091.19 | 44x | -143.9x | 4.2x |
| Thu, 10 Oct 2024 | HK$165.6b | HK$35.9b | -HK$655,249,294.09 | 30.7x | -252.7x | 4.6x |
| Sat, 07 Sep 2024 | HK$149.5b | HK$35.9b | -HK$658,597,307.62 | 23.4x | -227x | 4.2x |
| Mon, 05 Aug 2024 | HK$97.0b | HK$33.8b | HK$3.1b | 19.4x | 31x | 2.9x |
| Wed, 03 Jul 2024 | HK$87.7b | HK$33.4b | HK$3.1b | 17.5x | 28.5x | 2.6x |
| Fri, 31 May 2024 | HK$90.1b | HK$33.6b | HK$3.1b | 28x | 29.1x | 2.7x |
| Sun, 28 Apr 2024 | HK$108.0b | HK$33.6b | HK$3.1b | 30.6x | 34.9x | 3.2x |
| Tue, 26 Mar 2024 | HK$116.3b | HK$33.2b | HK$3.7b | 52.7x | 31.7x | 3.5x |
| Thu, 22 Feb 2024 | HK$134.2b | HK$32.3b | HK$3.0b | 56.8x | 45.1x | 4.2x |
| Sat, 20 Jan 2024 | HK$197.8b | HK$32.5b | HK$3.0b | 85.7x | 65.4x | 6.1x |
| Mon, 18 Dec 2023 | HK$212.6b | HK$32.5b | HK$3.0b | 85.2x | 70.5x | 6.5x |
| Wed, 15 Nov 2023 | HK$261.0b | HK$30.1b | HK$2.7b | 45.7x | 97.6x | 8.7x |
| Fri, 13 Oct 2023 | HK$265.0b | HK$30.1b | HK$2.7b | 47.4x | 99.1x | 8.8x |
| Sun, 10 Sep 2023 | HK$223.8b | HK$30.1b | HK$2.7b | 40.1x | 84.3x | 7.4x |
| Tue, 08 Aug 2023 | HK$235.8b | HK$28.4b | HK$2.7b | 22x | 86.5x | 8.3x |
| Thu, 06 Jul 2023 | HK$209.8b | HK$28.3b | HK$2.7b | 20.6x | 77.7x | 7.4x |
| Sat, 03 Jun 2023 | HK$235.5b | HK$28.9b | HK$2.8b | 20.9x | 83.6x | 8.1x |
| Mon, 01 May 2023 | HK$249.3b | HK$29.5b | HK$2.9b | 24.5x | 85.3x | 8.5x |
| Wed, 29 Mar 2023 | HK$251.7b | HK$28.9b | HK$2.5b | 23.3x | 102.7x | 8.7x |
| Fri, 24 Feb 2023 | HK$288.4b | HK$26.3b | HK$2.1b | 25x | 140.5x | 11x |
| Sun, 22 Jan 2023 | HK$371.2b | HK$26.6b | HK$2.1b | 27.8x | 174.2x | 14x |
Price to Earnings Ratio
174.2x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 57.5x which is higher than its 3-year average PE of 14.6x.
- The 3-year average PS ratio of 6.3x is lower than the industry's current PS ratio of 8.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 44% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 1.63% | |
| Healthcare | 4.28% | |
| Life Sciences | 11.41% | |
| Clinical Research and Equipment | 11.41% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$40.02 | 9.8% +HK$14.8b | 125.6% | PE35.2x | |
| 2268 WuXi XDC Cayman | HK$72.90 | 6.6% +HK$5.6b | 146.7% | PE61.6x | |
| 2228 XtalPi Holdings | HK$12.47 | 9.9% +HK$4.8b | 164.8% | PS70.4x | |
| 1548 Genscript Biotech | HK$14.28 | 1.4% +HK$437.3m | 54.7% | PE874.6x | |
| 1873 Viva Biotech Holdings | HK$2.07 | 10.1% +HK$401.0m | 162.0% | PE22.7x |
